These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 19758239

  • 1. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
    Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A.
    Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
    [Abstract] [Full Text] [Related]

  • 2. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL.
    Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A.
    QJM; 2008 Sep; 101(9):737-40. PubMed ID: 18650226
    [Abstract] [Full Text] [Related]

  • 3. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW, Kolesar JM.
    Clin Ther; 2009 Sep; 31 Pt 2():2290-311. PubMed ID: 20110042
    [Abstract] [Full Text] [Related]

  • 4. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
    Beum PV, Kennedy AD, Taylor RP.
    J Immunol Methods; 2004 Jun; 289(1-2):97-109. PubMed ID: 15251416
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia.
    Xu W, Miao KR, Zhu DX, Fang C, Zhu HY, Dong HJ, Wang DM, Wu YJ, Qiao C, Li JY.
    Int J Cancer; 2011 May 01; 128(9):2192-201. PubMed ID: 20635386
    [Abstract] [Full Text] [Related]

  • 7. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 01; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 8. Rituximab in chronic lymphocytic leukemia.
    Jaglowski SM, Byrd JC.
    Semin Hematol; 2010 Apr 01; 47(2):156-69. PubMed ID: 20350663
    [Abstract] [Full Text] [Related]

  • 9. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
    Gentile M, Lucia E, Iorio C, Vigna E, Mazzone C, Morelli R, Bisconte MG, Gentile C, Morabito F.
    Cancer Chemother Pharmacol; 2008 Sep 01; 62(4):741-3. PubMed ID: 18064461
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA, Minnie Pearl Cancer Research Network.
    J Clin Oncol; 2003 May 01; 21(9):1746-51. PubMed ID: 12721250
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ.
    Cancer; 2006 Sep 01; 107(5):916-24. PubMed ID: 16832816
    [Abstract] [Full Text] [Related]

  • 15. Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia.
    Wiernik PH, Adiga GU.
    Curr Med Res Opin; 2011 Oct 01; 27(10):1987-93. PubMed ID: 21905969
    [Abstract] [Full Text] [Related]

  • 16. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
    Mankaï A, Buhé V, Hammadi M, Youinou P, Ghedira I, Berthou C, Bordron A.
    Ann N Y Acad Sci; 2009 Sep 01; 1173():721-8. PubMed ID: 19758221
    [Abstract] [Full Text] [Related]

  • 17. High-dose rituximab therapy in chronic lymphocytic leukemia.
    Keating M, O'Brien S.
    Semin Oncol; 2000 Dec 01; 27(6 Suppl 12):86-90. PubMed ID: 11226005
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, Fanin R.
    Haematologica; 2002 Feb 01; 87(2):189-95. PubMed ID: 11836170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.